In the PENELOPE-B trial, the efficacy of adjuvant palbociclib was assessed in patients with hormone receptor-positive, HER2-negative breast cancer who exhibited residual disease following neoadjuvant chemotherapy. Here, ERBB2 is linked to breast carcinoma.